Extended-release ketamine tablets offer new hope for treatment-resistant depression

FHS
June 26, 2024
4:17 am

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

LR-19114 by LG Chem for Tetanus: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

June 18, 2024

Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot

November 14, 2023

GeneDx Launches AI Tool to Fuel Rare Disease Drug Discovery

What You Should Know: – GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to

November 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.